Skip to main content

Site notifications

RYTHMODAN disopyramide 100mg Capsules BP (Canada)

Section 19A approved medicine
RYTHMODAN disopyramide 100mg Capsules BP (Canada)
Section 19A approval holder
ORSPEC Pharma Pty Ltd ABN 15 634 980 417
Phone
02 4339 4239
Approved until
Status
Current
Medicines in short supply/unavailable
RYTHMODAN disopyramide 100 mg capsule blister pack - ARTG 13537
Indication(s)

Rythmodan capsules are indicated for the management of documented ventricular arrhythmias, such as sustained ventricular tachycardia, which are judged to be life threatening. Because of its proarrhythmic potential, the use of disopyramide is not recommended for lesser arrhythmias. Treatment of asymptomatic ventricular premature contractions should be avoided.

In patients with structural heart disease, proarrhythmia and cardiac decompensation are a special risk associated with antiarrhythmic medicines. Special caution should be exercised when prescribing disopyramide for these patients.

Images
Picture of RYTHMODAN disopyramide 100mg Capsules BP (Canada)

Help us improve the Therapeutic Goods Administration site